Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

Eli Lilly and Company (NYSE:LLY), a leading global pharmaceutical firm, finds itself at a pivotal juncture as it navigates a ...

Eli Lilly said that strong demand for these products, alongside robust performance ... Overall, non-incretin revenue saw a 20% year-over-year increase. Despite these gains, the company's 2024 ...

However, the strong revenue guidance ... Founded in 1876, Eli Lilly & Co. is a leading healthcare company that manufactures and sells pharmaceutical products worldwide. The company is ...

DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating on January 21.Invest with Confidence: Follow ...

Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity ...

2024 revenue is expected to be ... including with respect to Lilly's anticipated 2024 results and 2025 guidance, and specific product performance and supply, all of which are forward-looking ...

Perhaps most importantly, superior product efficacy is difficult ... the stock returns using the following inputs. Eli Lilly's trailing 12-month revenue of $40.86 billion will likely grow to ...

Eli Lilly cut its 2024 revenue guidance, saying demand for its obesity and diabetes drugs had not met its lofty expectations. Eli Lilly expects about $3.5 billion in revenue for its diabetes ...